Envista (NYSE:NVST) Shares Up 6.4% – Should You Buy?

Envista Holdings Corporation (NYSE:NVST) shares traded up 6.4% during mid-day trading on Wednesday . The stock traded as high as $28.80 and last traded at $28.6790. 1,429,926 shares were traded during trading, a decline of 51% from the average daily volume of 2,890,498 shares. The stock had previously closed at $26.96.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Piper Sandler reaffirmed a “neutral” rating and issued a $26.00 target price on shares of Envista in a research report on Wednesday. Citigroup assumed coverage on shares of Envista in a report on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 price objective for the company. Robert W. Baird lifted their price objective on Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday, May 7th. BMO Capital Markets initiated coverage on Envista in a report on Wednesday, July 8th. They set a “market perform” rating and a $27.00 target price on the stock. Finally, Zacks Research lowered shares of Envista from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Six research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.62.

Envista Trading Up 5.7%

The firm has a market capitalization of $4.64 billion, a PE ratio of 69.62, a P/E/G ratio of 1.51 and a beta of 0.86. The firm has a 50 day simple moving average of $25.34 and a 200 day simple moving average of $25.82. The company has a current ratio of 2.44, a quick ratio of 2.06 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.05. The firm had revenue of $705.50 million during the quarter, compared to analysts’ expectations of $680.03 million. Envista had a return on equity of 7.11% and a net margin of 2.41%.The company’s revenue was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Equities analysts expect that Envista Holdings Corporation will post 1.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Envista

Hedge funds have recently bought and sold shares of the business. Tudor Investment Corp ET AL purchased a new stake in Envista during the third quarter valued at $1,664,000. Massachusetts Financial Services Co. MA increased its holdings in shares of Envista by 15.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock worth $72,726,000 after buying an additional 444,725 shares during the last quarter. Royce & Associates LP lifted its position in Envista by 11.6% in the fourth quarter. Royce & Associates LP now owns 996,147 shares of the company’s stock worth $21,626,000 after buying an additional 103,312 shares during the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in shares of Envista during the fourth quarter valued at approximately $1,447,000. Finally, Intech Investment Management LLC bought a new position in Envista in the 4th quarter valued at $2,501,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.